HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion.

Additionally, tumors treated with the anti-HE4 mAb presented a greater percentage of effector CD8 + T cells than did control tumors, although the difference did not reach statistical significance, potentially because of the small sample size ( Figure 5 F).

also in 111,027 other papers